WP
RVNC

Woodline Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Woodline Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-797,953
Closed -$4.14M – 1019
2024
Q3 		$4.14M Buy
+797,953
New +$3.97M 0.03% 408
2023
Q3 		– Sell
-107,580
Closed -$2.72M – 773
2023
Q2 		$2.72M Buy
+107,580
New +$3.35M 0.03% 389
2021
Q4 		– Sell
-175,359
Closed -$4.89M – 807
2021
Q3 		$4.89M Buy
+175,359
New +$5M 0.08% 255

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Woodline Partners's RVNC Position: Q4 2024 in Review

Woodline Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 797,953 shares — an estimated $4.14M sold.

Woodline Partners first reported a position in RVNC in Q3 2021 and held it in 3 quarters. The position peaked at $4.89M in Q3 2021. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Woodline Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 797,953 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $4.14M.
  • Woodline Partners first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 3 quarters.
  • Woodline Partners's Revance Therapeutics, Inc. position peaked at $4.89M in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.